SCHEMBL2791341

SCHEMBL2791341

CCC1N=NS(=O)(=O)c2cc(Cl)ccc21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.37
CYP1A2 P05177 2/20 0.37
LMNA P02545 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
THRB P10828 1/20 0.37
TSHR P16473 1/20 0.37
ABCC8 Q09428 1/20 0.37
KCNJ11 Q14654 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
GRIA1 P42261 3/20 0.36
GRIA2 P42262 3/20 0.36
GRIA3 P42263 3/20 0.36
GRIA4 P48058 3/20 0.36
KDM4E B2RXH2 1/20 0.34
HPGD P15428 1/20 0.34
HSD17B10 Q99714 1/20 0.34
CA2 P00918 2/20 0.33
CA1 P00915 1/20 0.33
TAAR1 Q96RJ0 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2796293 0.80 ALDH1A1 (0.40) ALDH1A1CYP1A2LMNACYP3A4CYP2D6
SCHEMBL2793095 0.73 HTR1A (0.35)
SCHEMBL3575925 0.64 ALDH1A1 (0.40) ALDH1A1CYP1A2LMNACYP3A4CYP2D6
SCHEMBL3579238 0.63 CA1 (0.35) CA2CA1
SCHEMBL3587549 0.61 GRIA2 (0.39) ALDH1A1CYP1A2LMNACYP3A4CYP2D6
SCHEMBL3583177 0.59 CA2 (0.37) ALDH1A1CYP1A2LMNACYP3A4CYP2D6
SCHEMBL2792778 0.59 ALDH1A1 (0.38) ALDH1A1CYP1A2LMNACYP3A4CYP2D6
SCHEMBL2790682 0.58 CA2 (0.37) ALDH1A1LMNATSHRABCC8KCNJ11
SCHEMBL24090539 0.58 CA1 (0.42) ABCC8KCNJ11GRIA1GRIA2GRIA3
SCHEMBL720640 0.58 ALDH1A1 (0.66) ALDH1A1CYP1A2LMNACYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100190778-A1 3,4-DIHYDROBENZO[1,2,3]THIADIAZINE-1,1-DIOXIDE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, MEDICAMENTS CONTAINING SAID DERIVATIVES AND THEIR USE EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENTARSASAG (HU) 2010-07-29 US disclosed
US-20100168087-A1 BENZO[1,2,3]THIADIAZINE DERIVATES EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) 2010-07-01 US disclosed
EP-2061777-A1 BENZOÝ1,2,3¨THIADIAZINE DERIVATIVES Egis Gyogyszergyar Nyilvánosan Múködó Részvénytársaság (HU) 2009-05-27 EP disclosed
WO-2008020255-A1 BENZO[1,2,3]THIADIAZINE DERIVATIVES EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársagág (HU) 2008-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190778-A1 3,4-DIHYDROBENZO[1,2,3]THIADIAZINE-1,1-DIOXIDE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, MEDICAMENTS CONTAINING SAID DERIVATIVES AND THEIR USE TDO2, DHODH, DHPS ALDH1A1 45/4885CYP1A2 9/4885LMNA 3824/4885
US-20100168087-A1 BENZO[1,2,3]THIADIAZINE DERIVATES SULT2A1, TPH1, CYP1A1 ALDH1A1 39/4885CYP1A2 10/4885LMNA 4093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.